Metformina Eg Stada

Metformin, the active ingredient in Metformina Eg Stada, is a biguanide presented as a unknown/unknown for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Metformina Eg Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is used in the management of disorders related to glucose metabolism, particularly type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when used as part of lifestyle intervention. - Polycystic ovary syndrome (off‑label): helps reduce insulin resistance and may improve menstrual regularity.

Metformin is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycemia: usually when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: may develop with long‑term use. - Skin rash or hypersensitivity reactions. - Hepatic dysfunction: abnormal liver enzymes. - Acute pancreatitis: very rare occurrence.

When prescribing Metformina Eg Stada, several safety considerations should be observed.

- Renal function assessment: avoid or adjust dose in patients with impaired kidney function. - Monitor blood glucose: regular testing to avoid hypoglycemia, especially with combination therapy. - Hepatic function evaluation: use caution in patients with liver disease. - Elderly patients: start at lower dose and titrate slowly. - Contraindication in severe heart failure: increased risk of lactic acidosis. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Metformin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: may affect renal function, requiring monitoring. - NSAIDs: can reduce renal clearance of metformin. - Thiazide diuretics: may increase plasma glucose, requiring dose adjustment.